1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding Reports Financial Results For First Half year 2022

MAR

Q2 2022 KEY INDICATORS

  • Net sales amounted to 35.4MSEK (33.5)
  • EBITDA equalled 7.7 MSEK (4.0)
  • Operating profit (EBIT) is 4.0 MSEK (1.2)
  • Profit after tax amounted to 3.8 MSEK (0.7)
  • Earnings per share SEK 0.4 (0.1) per share

 
JAN-JUNE 2022 KEY INDICATORS

  • Net sales amounted to 65.7 MSEK (64.0)
  • EBITDA equalled 14.2 MSEK (7.5)
  • Operating profit (EBIT) is 7.5 MSEK (2.0)
  • Profit after tax amounted to 6.7 MSEK (1.8)
  • Earnings per share SEK 0.6 (0.1) per share

 
RECENT BUSINESS ACCOMPLISHMENTS

  • Agreement with Malmö Stad for expansion of the Malmö manufacturing site
  • Post-market clinical study of SmartPAN started
  • Commercial manufacturing start-up of AXXO WOUNDGEL
“Our second quarter results show development as we see the benefit of increased sales of our DSM proprietary medical products, as well as continued strong demand from international pharma and biotech companies for our pharmaceutical development and manufacturing services. I am pleased to see that the increased focus on DSM products is a contributing factor to financial performance in the first half of 2022, as this underpins that our underlying growth strategy is continuing to pay off,” says Justin Pierce, CEO of Magle Group.

 
 
 
 
 
 

Contacts

Megi Medzmariashvili, Legal Counsel, phone +46 (0)76 164 33 12, megi.medzmariashvili@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-17 08:00 CEST.

Attachments

220812 Q2 2022

Datum 2022-08-17, kl 08:00
Källa MFN
Bifogade filer
220812 Q2 2022
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet